ストックスクリーナーアプリを入手
2.01
4.29%
-0.09
Biocardia Inc (BCDA) 最新ニュース
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock - Investing.com India
Trial Results Show Autologous Cell Therapy Improves Survival, QOL and Reduces Cardiac Events in Distressed Heart Failure Patients - Diagnostic and Interventional Cardiology
Financial Analysis: BioCardia Inc (BCDA)’s Ratios Unveil Key Insights - DWinneX
BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Call Transcript - Insider Monkey
BioCardia Clarifies Timing for CardiAMP-HF Results Call - MSN
BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... - Yahoo Finance
ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains - Yahoo
BioCardia reports promising two-year CardiAMP trial results By Investing.com - Investing.com South Africa
Earnings call transcript: BioCardia Q4 2024 sees reduced expenses, stock down - Investing.com India
BioCardia Phase 3 CARDIAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years - HMP Global Learning Network
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - Barchart.com
Critical CardiAMP-HF 2-Year Data Reveal: Key Findings Presentation Today - Stock Titan
BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint - MarketScreener
BioCardia reports promising two-year CardiAMP trial results - Investing.com
BioCardia Reports Positive Phase 3 CardiAMP-HF Results - TipRanks
Breakthrough Heart Failure Treatment Shows 47% Death Risk Reduction in Phase 3 Trial - Stock Titan
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Beating Heart Patch Market Projected To Witness Substantial - openPR.com
BioCardia Reports 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings - GuruFocus
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - The Manila Times
BioCardia, Inc. to Report 2024 Financial Results and Host Conference Call Following CardiAMP-HF Trial Presentation - Nasdaq
SBA Communications (SBAC) Gets a Buy from Barclays - The Globe and Mail
MindMed Appoints Matt Wiley as Chief Commercial Officer - The Globe and Mail
Reviewing BioCardia (NASDAQ:BCDA) & Moderna (NASDAQ:MRNA) - Defense World
UiPath (PATH) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
BioCardia secures new Japanese patent for heart therapy delivery By Investing.com - Investing.com Australia
BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System -March 10, 2025 at 02:53 pm EDT - Marketscreener.com
BioCardia secures new Japanese patent for heart therapy delivery - Investing.com
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - The Manila Times
BioCardia announces Japanese patent for Helix system - TipRanks
BioCardia Wins Patent Protection in Japan for Novel Heart Therapy System - StockTitan
BioCardia director Simon Stertzer acquires $2,450 in stock By Investing.com - Investing.com Australia
BioCardia director Simon Stertzer acquires $2,450 in stock - Investing.com
Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia - TipRanks
Biocardia director Simon Stertzer acquires $88,064 in stock By Investing.com - Investing.com South Africa
Biocardia director Simon Stertzer acquires $88,064 in stock - Investing.com India
Biocardia CEO Peter Altman buys $1,055 in company stock - Investing.com
BioCardia Announces Primary Data Freeze For CardiAMP HF Phase 3 Trial For ACC 2025 Presentation - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia wraps up Phase 3 CardiAMP HF study data - Investing.com India
BioCardia finishes data freezing in heart failure therapy study for presentation - TipRanks
BioCardia Completes Source Data Verification for Phase 3 CardiAMP HF Study on Heart Failure Treatment - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in - GlobeNewswire
Will BioCardia's Cell Therapy Revolutionize Heart Failure Treatment? Phase 3 Data Coming Soon - StockTitan
BioCardia completes enrollment for heart therapy trial By Investing.com - Investing.com Canada
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - The Manila Times
BioCardia completes enrollment for heart therapy trial - Investing.com
BioCardia Reports Completion Of Low Dose Cohort Enrollment For Cardiallo Phase I/II Clinical Trial - Marketscreener.com
Clinical Trial Milestone: BioCardia's Revolutionary Heart Failure Treatment Advances to Next Phase - StockTitan
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Biocardia CEO Peter Altman acquires $1,488 in common stock - MSN
Biocardia CEO Peter Altman acquires $1,488 in stock By Investing.com - Investing.com Australia
10.70%
大文字化:
|
ボリューム (24 時間):